From mice to humans: developments in cancer immunoediting
Open accessAbstract
Cancer immunoediting explains the dual role by which the immune system can both suppress and/or promote tumor growth. Although cancer immunoediting was first demonstrated using mouse models of cancer, strong evidence that it occurs in human cancers is now accumulating. In particular, the importance of CD8+ T cells in cancer immunoediting has been shown, and more broadly in those tumors with an adaptive immune resistance phenotype. This Review describes the characteristics of the adaptive immune resistance tumor microenvironment and discusses data obtained in mouse and human settings. The role of other immune cells and factors influencing the effector function of tumor-specific CD8+ T cells is covered. We also discuss the temporal occurrence of cancer immunoediting in metastases and whether it differs from immunoediting in the primary tumor of origin.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Established tumors often arise through selection of clones able to evade the immune system (immunoediting).
“Established tumors are often thought to arise through the selection of clones that are able to evade the immune system, a process known as immunoediting (3).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863 · see citing works
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1× · see citing works
“Given the heterogeneity of tumors (61), it would be wise to vaccinate with a number of TSMAs, if possible, to reduce the emergence of escape variants.”
BackgroundPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · see citing works
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · see citing works
Self-citationCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · see citing works
Self-citationThe genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097 · see citing works
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · see citing works
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · see citing works
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981 · see citing works
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · see citing works
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M. J., Obenauf, A. C., Angell, H. K., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,390 · see citing works
Self-citationMolecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · see citing works
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · see citing works
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,373 · see citing works
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,036 · see citing works
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896 · see citing works
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324 · see citing works
Distinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225 · see citing works
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157 · see citing works
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135 · cited 1× · see citing works
“While tumor and traffic into tumors may lead to long-term immunity in human cancer (24, 25).”
BackgroundSelf-citationFeig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · see citing works
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,095 · see citing works
Self-citationCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974 · see citing works
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,710 · see citing works
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,699 · see citing works
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487 · see citing works
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471 · see citing works
Self-citationAdaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,438 · see citing works
Self-citationNeutrophil extracellular traps sequester circulating tumor cells and promote metastasis
Cools-Lartigue, J., Spicer, J., McDonald, B., Gowing, S., Chow, S., Giannias, B., Bourdeau, F., Kubes, P., & Ferri, L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67484 · Cited by 1,395 · see citing works
Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C., Lugli, A., Zlobec, I., Hartmann, A., Bifulco, C. B., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4287 · Cited by 1,358 · see citing works
Self-citationLoss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2006) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,341 · see citing works
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · see citing works
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,285 · see citing works
Self-citationPredicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186 · see citing works
Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W.-H., Pagès, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2907 · Cited by 1,146 · see citing works
Self-citationPD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,113 · see citing works
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081 · see citing works
CD4+ follicular helper T cell infiltration predicts breast cancer survival
Gu‐Trantien, C., Loi, S., Garaud, S., Equeter, C., Libin, M., de Wind, A., Ravoet, M., Buanec, H. L., Sibille, C., Manfouo-Foutsop, G., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67428 · Cited by 1,075 · see citing works
Dieu‐Nosjean, M., Antoine, M., Danel, C. J., Heudes, D., Wislez, M., Poulot, V., Rabbe, N., Laurans, L., Tartour, É., de Chaisemartin, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0284 · Cited by 1,033 · see citing works
Self-citationMlecnik, B., Tosolini, M., Kirilovsky, A., Berger, A., Bindea, G., Meatchi, T., Bruneval, P., Trajanoski, Z., Fridman, W.-H., Pagès, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5425 · Cited by 1,009 · see citing works
Self-citationIn Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer
Pagès, F., Kirilovsky, A., Mlecnik, B., Asslaber, M., Tosolini, M., Bindea, G., Lagorce, C., Wind, P., Marliot, F., Bruneval, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6147 · Cited by 953 · see citing works
Self-citationThe Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
Galon, J., Angell, H. K., Bedognetti, D., & Marincola, F. M. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.008 · Cited by 861 · see citing works
Self-citationGermain, C., Gnjatic, S., Tamzalit, F., Knockaert, S., Remark, R., Goc, J., Lepelley, A., Becht, E., Katsahian, S., Bizouard, G., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1611oc · Cited by 833 · see citing works
Self-citationRole of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity
Moyron‐Quiroz, J., Rangel‐Moreno, J., Kusser, K. L., Hartson, L., Sprague, F., Goodrich, S. P., Woodland, D. L., Lund, F. E., & Randall, T. D. (2004) · Nature Medicine · doi:10.1038/nm1091 · Cited by 815 · see citing works
Cancer classification using the Immunoscore: a worldwide task force
Galon, J., Pagès, F., Marincola, F. M., Angell, H. K., Thurin, M., Lugli, A., Zlobec, I., Berger, A., Bifulco, C. B., Botti, G., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-205 · Cited by 790 · see citing works
Self-citationB7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M., Cheng, P., Curiel, T., Myers, L., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050930 · Cited by 748 · see citing works
T-helper-1-cell cytokines drive cancer into senescence
Braumüller, H., Wieder, T., Brenner, E., Aßmann, S., Hahn, M., Alkhaled, M., Schilbach, K., Essmann, F., Kneilling, M., Griessinger, C., et al. (2013) · Nature · doi:10.1038/nature11824 · Cited by 720 · see citing works
Monte, L. B. D., Reni, M., Tassi, E., Clavenna, D., Papa, I., Recalde, H. R., Braga, M., Carlo, V. D., Doglioni, C., & Protti, M. P. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20101876 · Cited by 692 · see citing works
Mamessier, É., Sylvain, A., Thibult, M., Houvenaeghel, G. F., Jacquemier, J. D., Castellano, R., Gonçalvès, A., André, P., Romagné, F., Thibault, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45816 · Cited by 682 · see citing works
Goc, J., Germain, C., Vo-Bourgais, T. K. D., Mansuet‐Lupo, A., Klein, C., Knockaert, S., de Chaisemartin, L., Ouakrim, H., Becht, É., Alifano, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1342 · Cited by 675 · see citing works
Self-citationNakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H., & Ohtani, H. (2001) · PubMed · Cited by 639 · see citing works
Tertiary lymphoid structures in cancer and beyond
Dieu‐Nosjean, M., Goc, J., Giraldo, N. A., Sautès‐Fridman, C., & Fridman, W. H. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.09.006 · Cited by 616 · see citing works
Self-citationAngell, H., & Galon, J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.03.004 · Cited by 574 · see citing works
Self-citationImmunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
Lutz, E. R., Wu, A. A., Bigelow, E. O., Sharma, R. B., Mo, G., Soares, K. C., Solt, S., Dorman, A., Wamwea, A., Yager, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0027 · Cited by 551 · see citing works
Zhang, J., Yan, J., Xu, J., Pang, X.-H., Chen, M.-S., Li, L., Wu, C. Y., Li, S., & Zheng, L. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.033 · Cited by 535 · see citing works
Martinet, L., Garrido, I., Filleron, T., Guellec, S. L., Bellard, E., Fournié, J., Rochaix, P., & Girard, J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0431 · Cited by 523 · see citing works
Giraldo, N. A., Becht, É., Pagès, F., Skliris, G. P., Verkarre, V., Vano, Y. A., Méjean, A., Saint-Aubert, N., Lacroix, L., Natario, I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2926 · Cited by 517 · see citing works
Self-citationImmune Modulation in Cancer with Antibodies
Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P., & Wolchok, J. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112807 · Cited by 516 · see citing works
Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma
Platonova, S., Cherfils‐Vicini, J., Damotte, D., Crozet, L., Vieillard, V., Validire, P., André, P., Dieu‐Nosjean, M., Alifano, M., Régnard, J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4179 · Cited by 514 · see citing works
Self-citationStagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496 · see citing works
Self-citationLeukocyte composition of human breast cancer
Ruffell, B., Au, A., Rugo, H. S., Esserman, L. J., Hwang, E. S., & Coussens, L. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104303108 · Cited by 481 · see citing works
The parallel lives of angiogenesis and immunosuppression: cancer and other tales
Motz, G. T., & Coukos, G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3064 · Cited by 481 · see citing works
The Adaptive Immunologic Microenvironment in Colorectal Cancer: A Novel Perspective
Galon, J., Fridman, W. H., & Pagès, F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4806 · Cited by 447 · see citing works
Self-citationMilne, K., Köbel, M., Kalloger, S. E., Barnes, R. O., Gao, D., Gilks, C. B., Watson, P. H., & Nelson, B. H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006412 · Cited by 445 · see citing works
Cui, T. X., Kryczek, I., Zhao, L., Zhao, E., Kuick, R. D., Roh, M. H., Vatan, L., Szeliga, W., Mao, Y., Thomas, D. G., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.025 · Cited by 426 · see citing works
Halama, N., Michel, S., Kloor, M., Zoernig, I., Benner, A., Spille, A., Pommerencke, T., von Knebel, D. M., Folprecht, G., Luber, B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0268 · Cited by 421 · see citing works
Endogenous IL-17 contributes to reduced tumor growth and metastasis
Kryczek, I., Wei, S., Szeliga, W., Vatan, L., & Zou, W. (2009) · Blood · doi:10.1182/blood-2008-09-177360 · Cited by 403 · see citing works
Remark, R., Alifano, M., Cremer, I., Mansuet‐Lupo, A., Dieu‐Nosjean, M., Riquet, M., Crozet, L., Ouakrim, H., Goc, J., Cazes, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3847 · Cited by 391 · see citing works
Self-citationKryczek, I., Lin, Y., Nagarsheth, N., Peng, D., Zhao, L., Zhao, E., Vatan, L., Szeliga, W., Dou, Y., Owens, S. R., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.03.010 · Cited by 389 · see citing works
Caro, G. D., Bergomas, F., Grizzi, F., Doni, A., Bianchi, P. P., Malesci, A., Laghi, L., Allavena, P., Mantovani, A., & Marchesi, F. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2590 · Cited by 385 · see citing works
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Atefi, M. S., Avramis, E. V., Lassen, A., Wong, D. J. L., Robert, L., Foulad, D. S., Cerniglia, M., Titz, B., Chodon, T., Graeber, T. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2797 · Cited by 335 · see citing works
Ovarian cancer progression is controlled by phenotypic changes in dendritic cells
Scarlett, U. K., Rutkowski, M. R., Rauwerdink, A. M., Fields, J. L., Escovar-Fadul, X., Baird, J. R., Cubillos‐Ruiz, J. R., Jacobs, A., Gonzalez, J. L., Weaver, J. B., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20111413 · Cited by 314 · see citing works
Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence
Camus, M., Tosolini, M., Mlecnik, B., Pagès, F., Kirilovsky, A., Berger, A., Costes, A., Bindea, G., Charoentong, P., Bruneval, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2654 · Cited by 307 · see citing works
Self-citationB Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous Carcinomas
Affara, N. I., Ruffell, B., Medler, T. R., Gunderson, A. J., Johansson, M., Bornstein, S., Bergsland, E. K., Steinhoff, M. S., Li, Y., Gong, Q., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.026 · Cited by 305 · see citing works
Müller-Hermelink, N., Braumüller, H., Pichler, B., Wieder, T., Mailhammer, R., Schaak, K., Ghoreschi, K., Yazdi, A., Haubner, R., Sander, C. A., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.001 · Cited by 302 · see citing works
A proposed role for neutrophil extracellular traps in cancer immunoediting
Berger‐Achituv, S., Brinkmann, V., Abed, U. A., Kühn, L. I., Ben‐Ezra, J. M., Elhasid, R., & Zychlinsky, A. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00048 · Cited by 288 · see citing works
Fearon, D. T. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0002 · Cited by 288 · see citing works
Sæterdal, I., Bjørheim, J., Lislerud, K., Klemp, M., Bukholm, I. K., Olsen, O. C., Nesland, J. M., Eriksen, J. A., Møller, M., Lindblom, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231326898 · Cited by 273 · see citing works
Maldonado, L., Teague, J. E., Morrow, M. P., Jotova, I., Wu, T. ‐., Wang, C., Desmarais, C., Boyer, J., Tycko, B., Robins, H. S., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007323 · Cited by 252 · see citing works
Knuth, A., Danowski, B., Oettgen, H. F., & Old, L. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.11.3511 · Cited by 236 · see citing works
PRALL, F. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.01.022 · Cited by 226 · see citing works
Mlecnik, B., Bindea, G., Angell, H. K., Sasso, M. S., Obenauf, A. C., Fredriksen, T., Lafontaine, L., Bilocq, A. M., Kirilovsky, A., Tosolini, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007240 · Cited by 220 · see citing works
Self-citationSchlecker, E., Fiegler, N., Arnold, A., Altevogt, P., Rose‐John, S., Moldenhauer, G., Sucker, A., Paschen, A., von Strandmann, E. P., Textor, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3017 · Cited by 216 · see citing works
Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients
Chen, X., Wan, J., Liu, J., Xie, W., Diao, X., Xu, J., Zhu, B., & Chen, Z. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.11.013 · Cited by 215 · see citing works
Mechanisms of Hypoxia-Mediated Immune Escape in Cancer
Barsoum, I. B., Koti, M., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2598 · Cited by 201 · see citing works
Higher levels of GATA3 predict better survival in women with breast cancer
Yoon, N. K., Maresh, E. L., Shen, D., Elshimali, Y., Apple, S. K., Horvath, S., Mah, V. H., Bose, S., Chia, D., Chang, H. R., et al. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.06.010 · Cited by 195 · see citing works
Yang, J., Murphy, T. L., Ouyang, W., & MURPHY, K. M. M. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199902)29:02 · Cited by 195 · see citing works
Prognostic impact of tumour‐infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma
Schreck, S., Friebel, D., Buettner, M. J., Distel, L. V., Grabenbauer, G. G., Young, L. S., & Niedobitek, G. (2008) · Hematological Oncology · doi:10.1002/hon.878 · Cited by 189 · see citing works
Ubukata, H., Motohashi, G., Tabuchi, T., Nagata, H., Konishi, S., & Tabuchi, T. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21725 · Cited by 175 · see citing works
Genetic evolution of T-cell resistance in the course of melanoma progression
Sucker, A., Zhao, F., Real, B., Heeke, C., Bielefeld, N., Maβen, S., Horn, S., Moll, I., Maltaner, R., Horn, P. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0567 · Cited by 171 · see citing works
Ferradini, L., Mackensen, A., Genevée, C., Bosq, J., Duvillard, P., Avril, M.-F., & Hercend, T. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116278 · Cited by 142 · see citing works
The immune contexture of primary and metastatic human tumours
Giraldo, N. A., Becht, É., Remark, R., Damotte, D., Sautès‐Fridman, C., & Fridman, W. H. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.001 · Cited by 140 · see citing works
Self-citationTanchot, C., Terme, M., Pere, H., Tran, T., Benhamouda, N., Strioga, M., Banissi, C., Galluzzi, L., Kroemer, G., & Tartour, E. (2013) · Cancer Microenvironment · doi:10.1007/s12307-012-0122-y · Cited by 138 · cited 1× · see citing works
“It may reflect the heterogeneity of Treg subsets (96) in the tumor microenvironment or the selectivity of Treg markers (97).”
BackgroundLv, L. L., Pan, K., Li, X.-D., She, K.-L., Zhao, J.-J., Wang, W., Chen, J.-G., Chen, Y.-B., Yun, J., & Xia, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018219 · Cited by 133 · see citing works
Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State
Teng, M. W. L., Vesely, M. D., Duret, H., McLaughlin, N. M., Towne, J. E., Schreiber, R. D., & Smyth, M. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1337 · Cited by 118 · see citing works
Self-citationIoannides, C. G., Fisk, B. A., Fan, D., Biddison, W. E., Wharton, J. T., & O’Brian, C. A. (1993) · Cellular Immunology · doi:10.1006/cimm.1993.1233 · Cited by 118 · see citing works
A balance of interleukin-12 and -23 in cancer
Ngiow, S. F., Teng, M. W. L., & Smyth, M. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.004 · Cited by 116 · see citing works
Self-citationThe Emerging “Hallmarks” of Metabolic Reprogramming and Immune Evasion: Distinct or Linked?
Kareva, I., & Hahnfeldt, P. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3696 · Cited by 111 · see citing works
Positive and negative influence of the matrix architecture on antitumor immune surveillance
Peranzoni, E., Rivas-Caicedo, A., Bougherara, H., Salmon, H., & Donnadieu, E. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1339-8 · Cited by 108 · see citing works
Antitumour immunity gets a boost
Wolchok, J. D., & Chan, T. A.-T. (2014) · Nature · doi:10.1038/515496a · Cited by 108 · see citing works
Intratumoral Expression of IL-17 and Its Prognostic Role in Gastric Adenocarcinoma Patients
Chen, J.-G., Xia, J., Liang, X.-T., Pan, K., Wang, W. T., Lv, L. L., Zhao, J.-J., Wang, Q.-J., Li, Y.-Q., Chen, S.-P., et al. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.53 · Cited by 108 · see citing works
Kusuda, T., Shigemasa, K., Arihiro, K., Fujii, T., Nagai, N., & Ohama, K. (2005) · Oncology Reports · doi:10.3892/or.13.6.1153 · Cited by 101 · see citing works
Pastille, E., Bardini, K., Fleissner, D., Adamczyk, A., Frede, A., Wadwa, M., von Smolinski, D., Kasper, S., Sparwasser, T. D., Gruber, A. D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3065 · Cited by 101 · see citing works
Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma.
Whelchel, J. C., Farah, S., McLean, I. W., & Burnier, M. N. (1993) · PubMed · Cited by 98 · see citing works
Evolution of the Immune System in the Lower Vertebrates
Boehm, T. L. J., Iwanami, N., & Hess, I. (2012) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090711-163747 · Cited by 89 · see citing works
Interleukin-17D Mediates Tumor Rejection through Recruitment of Natural Killer Cells
O’Sullivan, T. E., Saddawi‐Konefka, R., Gross, E. T. E., Tran, M., Mayfield, S. P., Ikeda, H., & Bui, J. D. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.073 · Cited by 88 · see citing works
Asano, N., Oshiro, A., Matsuo, K., Kagami, Y., Ishida, F., Suzuki, R., Kinoshita, T., Shimoyama, Y., Tamaru, J., Yoshino, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5342 · Cited by 88 · see citing works
Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer
Lavoué, V., Thedrez, A., Lévêque, J., Foucher, F., Henno, S., Jauffret, V., Belaud‐Rotureau, M., Catros, V., & Cabillic, F. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-147 · Cited by 64 · see citing works
Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses
Goc, J., Fridman, W. H., Hammond, S. A., Sautès‐Fridman, C., & Dieu‐Nosjean, M. (2014) · OncoImmunology · doi:10.4161/onci.28976 · Cited by 46 · see citing works
Self-citationLy49 Family Receptors Are Required for Cancer Immunosurveillance Mediated by Natural Killer Cells
Tu, M. M., Mahmoud, A. B., Wight, A. E., Mottashed, A., Bélanger, S., Rahim, M. M. A., Abou-Samra, E., & Makrigiannis, A. P. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3021 · Cited by 41 · see citing works
NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma
von Boehmer, L., Mattle, M., Bode, P. K., Landshammer, A., Schäfer, C., Nuber, N., Ritter, G., Old, L. J., Moch, H., Schäfer, N., et al. (2013) · Europe PMC (PubMed Central) · doi:10.5167/uzh-79657 · Cited by 27 · see citing works
Oncogene addiction and immunity
Savas, P. S., Caramia, F., Teo, Z. L., & Loi, S. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000131 · Cited by 21 · see citing works
Cutaneous Tumors Cease CXCL9/Mig Production as a Result of IFN-γ–Mediated Immunoediting
Petro, M., Kish, D. D., Guryanova, O. A., Ilyinskaya, G. V., Kondratova, A. A., Fairchild, R. L., & Gorbachev, A. V. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201906 · Cited by 19 · see citing works
Pembrolizumab Shows Potential in Breast Cancer
(2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2014-184 · Cited by 5 · see citing works
Flagged first, then by citations
2 of the 123 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Dunn GP, Old LJ, Schreiber RD. The immunobiol- ogy of cancer immunosurveillance and immuno- editing. Immunity. 2004;21(2):137-148.
- Zorn E, Hercend T. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol. 1999;29(2):592-601.
Cited by
Sorted by citations
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111 · see citing works
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759 · see citing works
Self-citationThe multifaceted roles of fatty acid synthesis in cancer
Röhrig, F., & Schulze, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.89 · Cited by 1,651 · see citing works
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360 · see citing works
Cancer immunotherapy: harnessing the immune system to battle cancer
Yang, Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83871 · Cited by 1,366 · see citing works
Schirrmacher, V. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4661 · Cited by 1,303 · see citing works
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944 · see citing works
Self-citationJiménez-Sánchez, A., Memon, D., Pourpe, S., Veeraraghavan, H., Li, Y., Vargas, H. A., Gill, M. B., Park, K. J., Zivanovic, O., Konner, J. A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.025 · Cited by 449 · see citing works
B lymphocytes and cancer: a love-hate relationship
Yuen, G. J., Demissie, E., & Pillai, S. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.10.010 · Cited by 433 · see citing works
Tertiary lymphoid structures, drivers of the anti‐tumor responses in human cancers
Dieu‐Nosjean, M., Giraldo, N. A., Kaplon, H., Germain, C., Fridman, W. H., & Sautès‐Fridman, C. (2016) · Immunological Reviews · doi:10.1111/imr.12405 · Cited by 417 · see citing works
Self-citationHypoxia and the Tumor Microenvironment
Li, Y., Zhao, L., & Li, X.-F. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211036304 · Cited by 397 · see citing works
Current status and future directions of cancer immunotherapy
Zhang, H., & Chen, J. (2018) · Journal of Cancer · doi:10.7150/jca.24577 · Cited by 348 · see citing works
The concept of immune surveillance against tumors: The first theories
Ribatti, D. (2016) · Oncotarget · doi:10.18632/oncotarget.12739 · Cited by 334 · see citing works
Xu, X., Yousef, G. M., & Ni, H. (2018) · Blood · doi:10.1182/blood-2017-05-743187 · Cited by 324 · see citing works
Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma
Maibach, F., Sadozai, H., Jafari, S. M. S., Hunger, R. E., & Schenk, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02105 · Cited by 312 · see citing works
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Saleh, R., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.017 · Cited by 292 · see citing works
Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
Efremova, M., Rieder, D., Klepsch, V., Charoentong, P., Finotello, F., Hackl, H., Hermann‐Kleiter, N., Löwer, M., Baier, G., Krogsdam, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02424-0 · Cited by 295 · see citing works
Aging and cancer: The role of macrophages and neutrophils
Jackaman, C., Tomay, F., Duong, L., Abdol Razak, N. B., Pixley, F. J., Metharom, P., & Nelson, D. J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.03.008 · Cited by 251 · see citing works
Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.568931 · Cited by 243 · see citing works
Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
Ralli, M., Botticelli, A., Visconti, I. C., Angeletti, D., Fiore, M., Marchetti, P., Lambìase, A., VINCENTIIS, M. D., & Greco, A. (2020) · Journal of Immunology Research · doi:10.1155/2020/9235638 · Cited by 247 · see citing works
Treg-mediated acquired resistance to immune checkpoint inhibitors
Saleh, R., & Elkord, E. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.003 · Cited by 238 · see citing works
Ward, J. P., Gubin, M. M., & Schreiber, R. D. (2016) · Advances in immunology · doi:10.1016/bs.ai.2016.01.001 · Cited by 228 · see citing works
T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy
Sackstein, R., Schatton, T., & Barthel, S. R. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.25 · Cited by 213 · see citing works
Becht, É., Giraldo, N. A., Germain, C., de Reyniès, A., Laurent‐Puig, P., Zucman‐Rossi, J., Dieu‐Nosjean, M., Sautès‐Fridman, C., & Fridman, W. H. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.002 · Cited by 213 · see citing works
Self-citationNeoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
Efremova, M., Finotello, F., Rieder, D., & Trajanoski, Z. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01679 · Cited by 211 · see citing works
The Interferon-Gamma Paradox in Cancer
Zaidi, M. R. (2018) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0087 · Cited by 200 · see citing works
Hendry, S. A., Farnsworth, R. H., Solomon, B., Achen, M. G., Stacker, S. A., & Fox, S. B. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00621 · Cited by 188 · see citing works
Xu, Y., Xiong, J., Sun, X., & Gao, H. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.001 · Cited by 187 · see citing works
Gangemi, S., Gofiţă, E., Costa, C., Teodoro, M., Briguglio, G., Nikitovic, D., Tzanakakis, G. N., Tsatsakis, A. M., Wilks, M. F., Spandidos, D. A., et al. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2728 · Cited by 181 · see citing works
CXCL9: evidence and contradictions for its role in tumor progression
Ding, Q., Lu, P., Xia, Y., Ding, S., Fan, Y., Li, X., Han, P., Liu, J., Tian, D., & Liu, M. (2016) · Cancer Medicine · doi:10.1002/cam4.934 · Cited by 164 · see citing works
Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells
Wu, L., Wei, Q., Brzostek, J., & Gascoigne, N. R. J. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0470-3 · Cited by 153 · see citing works
Reactive Oxygen Species and Antitumor Immunity—From Surveillance to Evasion
Kotsafti, A., Scarpa, M., Castagliuolo, I., & Scarpa, M. (2020) · Cancers · doi:10.3390/cancers12071748 · Cited by 157 · see citing works
Cancer Immunoediting in the Era of Immuno-oncology
Gubin, M. M., & Vesely, M. D. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1804 · Cited by 146 · see citing works
Immune Checkpoint Inhibitors in Human Glioma Microenvironment
Ghouzlani, A., Kandoussi, S., Tall, M., Reddy, K. P., Rafii, S., & Badou, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679425 · Cited by 142 · see citing works
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 141 · see citing works
Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment
Gao, Z., Bai, Y., Lin, A., Jiang, A., Zhou, C., Cheng, Q., Liu, Z., Chen, X., Zhang, J., & Luo, P. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01722-0 · Cited by 138 · see citing works
TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
Sauer, N. J., Janicka, N., Szlasa, W., Skinderowicz, B., Kołodzińska, K., Dwernicka, W., Oślizło, M., Kulbacka, J., Novickij, V., & Karłowicz-Bodalska, K. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03516-1 · Cited by 138 · see citing works
Morrot, A., da Fonseca, L. M., Salustiano, E. J., Gentile, L. B., Conde, L., Filardy, A. A., Franklim, T. N., da Costa, K. M., Freire-de-Lima, C. G., & Freire‐de‐Lima, L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00081 · Cited by 126 · see citing works
Potential Contributions of Antioxidants to Cancer Therapy: Immunomodulation and Radiosensitization
Thyagarajan‐Sahu, A., & Sahu, R. P. (2017) · Integrative Cancer Therapies · doi:10.1177/1534735416681639 · Cited by 126 · see citing works
Li, T., Li, K., Zhang, Q., Wang, C., Yue, Y., Chen, Z., Yuan, S.-J., Liu, X., Wen, Y., Han, M. H., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.07.035 · Cited by 126 · see citing works
Long noncoding RNAs in cancer‐immunity cycle
Yu, W., Wang, H., He, Q., Xu, Y., & Wang, X. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26568 · Cited by 124 · see citing works
Immunogenic cell death in colon cancer prevention and therapy
Ruan, H., Leibowitz, B. J., Zhang, L., & Yu, J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23183 · Cited by 122 · see citing works
Bashraheel, S. S., Dömling, A. S. S., & Goda, S. K. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110009 · Cited by 122 · see citing works
Combination therapy based on nano codelivery for overcoming cancer drug resistance
Wang, H., & Huang, Y. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100024 · Cited by 115 · see citing works
Ribatti, D. (2017) · Springer eBooks · doi:10.1007/978-3-319-68448-2_5 · Cited by 115 · see citing works
Tertiary Lymphoid Organs in Cancer Tissues
Hiraoka, N., Ino, Y., & Yamazaki-Itoh, R. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00244 · Cited by 105 · see citing works
Yagyuu, T., Hatakeyama, K., Imada, M., Kurihara, M., Matsusue, Y., Yamamoto, K., Obayashi, C., & Kirita, T. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.03.006 · Cited by 101 · see citing works
Mello, P. D. A., Coutinho‐Silva, R., & Savio, L. E. B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01526 · Cited by 100 · see citing works
Oliveira, M. F., Romero, J. P., Chung, M., Williams, S., Gottscho, A. D., Gupta, A., Pilipauskas, S. E., Mohabbat, S., Raman, N., Sukovich, D., et al. (2024) · doi:10.1101/2024.06.04.597233 · Cited by 95 · see citing works
Tan, D. S. W., Felip, E., de Castro, G., Solomon, B., Greystoke, A., Cho, B. C., Cobo, M., Kim, T. M., Ganguly, S., Carcereny, E., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00980 · Cited by 97 · see citing works
Zalfa, C., & Paust, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633205 · Cited by 95 · see citing works
Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
Chocarro, L., Zuazo, M., Arasanz, H., Bocanegra, A., Hernandez, C., Fernández, G., García-Granda, M. J., Blanco, E., Vera, R., Kochan, G. T., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00441 · Cited by 92 · see citing works
Zeng, W., Zhang, L., Cao, H., Li, D., Zhang, H., Xia, Z., & Peng, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.810572 · Cited by 92 · see citing works
Obesity-related T cell dysfunction impairs immunosurveillance and increases cancer risk
Piening, A., Ebert, E. C., Gottlieb, C., Khojandi, N., Kuehm, L. M., Hoft, S. G., Pyles, K. D., McCommis, K. S., DiPaolo, R. J., Ferris, S. T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47359-5 · Cited by 95 · see citing works
Crosstalk between Macrophages, T Cells, and Iron Metabolism in Tumor Microenvironment
Shen, L., Zhou, Y., He, H., Chen, W., Lenahan, C., Li, X., Deng, Y., Shao, A., & Huang, J. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/8865791 · Cited by 90 · see citing works
Breast Cancer Vaccines: Disappointing or Promising?
Zhu, S., & Yu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828386 · Cited by 93 · see citing works
TH9 cells in anti-tumor immunity
Vargas, T. R., Humblin, É., Végran, F., Ghiringhelli, F., & Apétoh, L. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0599-4 · Cited by 88 · see citing works
PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
Šmahel, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061331 · Cited by 82 · see citing works
Boxberg, M., Leising, L., Steiger, K., Jesinghaus, M., Alkhamas, A., Mielke, M., Pfarr, N., Götz, C., Wolff, K. D., Weichert, W., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800242 · Cited by 79 · see citing works
Colorectal cancer prevention: Immune modulation taking the stage
Fletcher, R., Wang, Y., Schoen, R. E., Finn, O. J., Yu, J., & Zhang, L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.12.002 · Cited by 77 · see citing works
Xu, H., Lin, S., Zhou, Z., Li, D., Zhang, X., Yu, M., Zhao, R., Wang, Y., Qian, J., Li, X., et al. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01032-x · Cited by 77 · see citing works
Role of CXC group chemokines in lung cancer development and progression
Špaks, A. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.03.61 · Cited by 71 · see citing works
Haas, O. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03136 · Cited by 70 · see citing works
Advances in the interaction of glycolytic reprogramming with lactylation
Li, Y., Cao, Q., Hu, Y., He, B., Cao, T., Tang, Y., Zhou, X. P., Lan, X. P., & Liu, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116982 · Cited by 68 · see citing works
Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy
Czajka‐Francuz, P., Prendes, M. J., Mankan, A. K., Quintana, Á., Pabla, S., Ramkissoon, S. H., Jensen, T. J., Peiró, S., Severson, E. A., Achyut, B. R., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1200646 · Cited by 69 · see citing works
The Immunoregulatory Potential of Particle Radiation in Cancer Therapy
Ebner, D. K., Tinganelli, W., Helm, A., Bisio, A., Yamada, S., Kamada, T., Shimokawa, T., & Durante, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00099 · Cited by 66 · see citing works
Sculpting tumor microenvironment with immune system: from immunometabolism to immunoediting
Yu, Y.-R., & Ho, P. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13293 · Cited by 64 · see citing works
Degnim, A. C., Hoskin, T. L., Arshad, M., Frost, M. H., Winham, S. J., Brahmbhatt, R. A., Peña, A., Carter, J. M., Stallings‐Mann, M. L., Murphy, L. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2026 · Cited by 65 · see citing works
The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response
Cascini, C., & Chiodoni, C. (2021) · Cells · doi:10.3390/cells10071668 · Cited by 63 · see citing works
Leveraging premalignant biology for immune-based cancer prevention
Spira, A. E., Disis, M. L., Schiller, J. T., Vilar, E., Rebbeck, T. R., Bejar, R. L., Ideker, T. E., Arts, J., Yurgelun, M. B. B., Mesirov, J. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608077113 · Cited by 63 · see citing works
Electroporation and Immunotherapy—Unleashing the Abscopal Effect
Justesen, T. F., Orhan, A., Raskov, H., Nolsøe, C., & Gögenür, I. (2022) · Cancers · doi:10.3390/cancers14122876 · Cited by 63 · see citing works
Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research
Overgaard, N. H., Fan, T. M., Schachtschneider, K. M., Principe, D. R., Schook, L. B., & Jungersen, G. (2018) · ILAR Journal · doi:10.1093/ilar/ily014 · Cited by 63 · see citing works
Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
Pagni, F., Guerini‐Rocco, E., Schultheis, A. M., Grazia, G., Rijavec, E., Ghidini, M., Lopez, G., Venetis, K., Croci, G. A., Malapelle, U., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215452 · Cited by 61 · see citing works
Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma
Sadozai, H., Gruber, T., Hunger, R. E., & Schenk, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01617 · Cited by 60 · see citing works
Haworth, K. B., Arnold, M., Pierson, C. R., Choi, K., Yeager, N. D., Ratner, N., Roberts, R. D., Finlay, J. L., & Cripe, T. P. (2017) · Oncotarget · doi:10.18632/oncotarget.18301 · Cited by 61 · see citing works
Chaperone-assisted E3 ligase CHIP: A double agent in cancer
Kumar, S., Basu, M., & Ghosh, M. K. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.003 · Cited by 57 · see citing works
Novel therapeutic strategies for spinal osteosarcomas
Anwar, M. A., El‐Baba, C., Elnaggar, M. H., Elkholy, Y. O., Mottawea, M., Johar, D., Shehabi, T. S. A., Kobeissy, F. H., Moussalem, C. K., Massaad, E., et al. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.018 · Cited by 57 · see citing works
Zhang, W., Wang, S., Wang, H., Tang, Y.-J., Tang, Y., & Liang, X. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.111634 · Cited by 57 · see citing works
Zheng, D., Wan, C., Yang, H., Xu, L., Dong, Q., Du, C., Du, J., & Li, F. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s271213 · Cited by 56 · see citing works
P2 receptors in cancer progression and metastatic spreading
Virgilio, F. D., Falzoni, S., Giuliani, A. L., & Adinolfi, E. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.05.001 · Cited by 54 · see citing works
Extracellular vesicles in lung cancer—From bench to bedside
Kadota, T., Yoshioka, Y., Fujita, Y., Kuwano, K., & Ochiya, T. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.03.001 · Cited by 54 · see citing works
The Janus Face of Death Receptor Signaling during Tumor Immunoediting
Reilly, E. O., Tirincsi, A., Logue, S. E., & Szegezdi, É. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00446 · Cited by 53 · see citing works
Update in TIGIT Immune-Checkpoint Role in Cancer
Annese, T., Tamma, R., & Ribatti, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871085 · Cited by 50 · see citing works
Akbarpour, M., Khalyfa, A., Qiao, Z., Gileles‐Hillel, A., Almendros, I., Farré, R., & Gozal, D. (2016) · SLEEP · doi:10.1093/sleep/zsw040 · Cited by 48 · see citing works
Kareva, I. (2019) · Stem Cells · doi:10.1002/stem.3051 · Cited by 48 · see citing works
Jin, M., Yuan, S., Yuan, Y., & Yi, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.735803 · Cited by 48 · see citing works
Yahiro, K., Matsumoto, Y., Yamada, H., Endo, M., Setsu, N., Fujiwara, T., Nakagawa, M., Kimura, A., Shimada, E., Okada, S., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02508-9 · Cited by 47 · see citing works
Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy
Pérez-Romero, K., Rodríguez, R. M., Amedei, A., Barceló-Coblijn, G., & López, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155521 · Cited by 42 · see citing works
Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer
Telli, M. L., Stover, D. G., Loi, S., Aparicio, S. A. J. R., Carey, L., Domchek, S. M., Newman, L. A., Sledge, G. W., & Winer, E. P. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4807-x · Cited by 45 · see citing works
Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia
Jiménez‐Morales, S., Aranda-Uribe, I. S., Pérez-Amado, C. J., Ramírez‐Bello, J., & Hidalgo‐Miranda, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737340 · Cited by 46 · see citing works
Voronova, V., Vislobokova, A., Mutig, K., Samsonov, M., Peskov, K. V., Sekacheva, M. I., Materenchuk, M. Y., Bunyatyan, N. D., & Lebedeva, S. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1035884 · Cited by 46 · see citing works
Zolkind, P., Przybylski, D., Marjanovic, N. D., Nguyễn, L., Lin, T., Johanns, T. M., Alexandrov, A., Zhou, L., Allen, C. T., Miceli, A. P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23751 · Cited by 43 · see citing works
Gigoux, M., Holmström, M. O., Zappasodi, R., Park, J. J., Pourpe, S., Bozkus, C. C., Mangarin, L. M. B., Redmond, D., Verma, S., Schad, S. E., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.aba4380 · Cited by 41 · see citing works
Cell Competition in Carcinogenesis
Madan, E., Palma, A. M., Vudatha, V., Trevino, J. G., Natarajan, K. N., Winn, R. A., Won, K., Graham, T. A., Drapkin, R., McDonald, S. A. C., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2217 · Cited by 41 · see citing works
Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications
Gupta, I., Hussein, O., Sastry, K. S., Bougarn, S., Gopinath, N., Chin-Smith, E. C., Sinha, Y., Korashy, H. M., & Maccalli, C. (2023) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2023.100107 · Cited by 37 · see citing works
Cancer immunoediting hypothesis: history, clinical implications and controversies
Lasek, W. (2022) · Central European Journal of Immunology · doi:10.5114/ceji.2022.117376 · Cited by 39 · see citing works
Andreuzzi, E., Fejza, A., Polano, M., Poletto, E., Camicia, L., Carobolante, G., Tarticchio, G., Todaro, F., Carlo, E. D., Scarpa, M., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02271-y · Cited by 35 · see citing works
Overview of Research and Development for Anticancer Drugs
Xu, J., & Mao, W.-W. (2016) · Journal of Cancer Therapy · doi:10.4236/jct.2016.710077 · Cited by 31 · see citing works
Tu, Y., Johnstone, C. N., & Stewart, A. G. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.011 · Cited by 34 · see citing works
PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
Tarantelli, C., Argnani, L., Zinzani, P. L., & Bertoni, F. (2021) · Cancers · doi:10.3390/cancers13215535 · Cited by 35 · see citing works
- Authors
- Teng, M. W. L., Galon, J., Fridman, W.-H., & Smyth, M. J.
- Affiliations
- The University of Queensland (AU)
- Inserm (FR)
- Venue
- Journal of Clinical Investigation
- Published
- 2015-08-04
- Volume
- 125
- Issue
- 9
- Pages
- 3338-3346
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4588291
- OpenAlex
- W1923943509
- Cited by
- 337
- References
- 123
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 29 · 2023: 33 · 2022: 45 · 2021: 42 · 2020: 40 · 2019: 26 · 2018: 27 · 2017: 41 · 2016: 26 · 2015: 2
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Prostate Cancer Foundation
- Prostate Cancer Foundation of Australia
- Medical Research Council
- National Health and Medical Research Council (1013667, 1059862, 1078671, 1021139)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cancer immunoediting, tumor immune microenvironment, CD8+ T cells, adaptive immune resistance, metastasis, primary tumor, mouse tumor model, human cancer
- MeSH terms
- Animals, Humans, Neoplasms, CD8-Positive T-Lymphocytes, Mice, Adaptive Immunity, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
